Adaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer Patients
Portfolio Pulse from
Adaptive Biotechnologies and NeoGenomics have partnered to enhance personalized disease monitoring for blood cancer patients by combining Adaptive's clonoSEQ MRD results with NeoGenomics' COMPASS and CHART assessment services.
January 14, 2025 | 12:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Adaptive Biotechnologies partners with NeoGenomics to integrate clonoSEQ MRD results with COMPASS and CHART services, enhancing personalized disease monitoring for blood cancer patients.
The partnership with NeoGenomics is likely to enhance Adaptive Biotechnologies' product offering and market reach, potentially increasing demand for its clonoSEQ MRD results.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
NeoGenomics partners with Adaptive Biotechnologies to integrate COMPASS and CHART services with clonoSEQ MRD results, improving personalized disease monitoring for blood cancer patients.
The collaboration with Adaptive Biotechnologies is expected to strengthen NeoGenomics' service offerings, potentially increasing its market share and customer base.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 80